Neuphoria Therapeutics Inc.
Company Information
Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting companyEmerging growth company
State of Incorporation Australia
Business Address 100 SUMMIT DR, BURLINGTON, MA, 01803
Mailing Address 100 SUMMIT DR, BURLINGTON, MA, 01803
Phone 781-439-5551
Fiscal Year End 0630
EIN 000000000
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| SCHEDULE 13G/A Passive ownership amendment | February 6, 2026 | View on SEC |
| 4 Insider stock transaction report | January 21, 2026 | View on SEC |
| 4 Insider stock transaction report | January 21, 2026 | View on SEC |
| 4 Insider stock transaction report | January 21, 2026 | View on SEC |
| 4 Insider stock transaction report | January 21, 2026 | View on SEC |
| 8-K Current report of material events | January 8, 2026 | View on SEC |
| SCHEDULE 13D/A Beneficial ownership amendment | December 29, 2025 | View on SEC |
| 8-K Current report of material events | December 18, 2025 | View on SEC |
| 8-K Current report of material events | December 17, 2025 | View on SEC |
| SCHEDULE 13D/A Beneficial ownership amendment | December 2, 2025 | View on SEC |
Annual Reports
10-K September 29, 2025
- Phase 2 PTSD/anxiety trials showed promise for BNC210.
- Fast Track status granted by FDA for BNC210 development.
Material Events
8-K Leadership Change January 8, 2026
High Impact
- Neuphoria Therapeutics Inc.'s President and CEO, Spyridon "Spyros" Papapetropoulos, is stepping down from his full-time role.
- Mr. Papapetropoulos will remain on the Board of Directors and serve as interim CEO for up to one year to guide a potential "strategic transaction."
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.